Year: 2020

Diese Auszeichnung würdigt das Engagement von Roche für Nachhaltigkeit als integraler Bestandteil der GeschäftsstrategieRoche überzeugte insbesondere in den Bereichen Marketingpraktiken, Umwelt- und Sozialberichterstattung, Öko-Effizienz, Klimastrategie sowie Gesellschaftliches Engagement und Philanthropie             Basel, 16. November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) wurde zum elften Mal zum nachhaltigsten Unternehmen der Pharmaindustrie im Dow Jones Sustainability Index (DJSI) gekürt. Die Auszeichnung basiert auf einer umfassenden Bewertung der wirtschaftlichen, sozialen und ökologischen Leistungsfähigkeit des Unternehmens. Der Dow Jones Sustainability Index dient als Vergleichsindex für Investoren, die ihr Portfolio nach nachhaltigen Kriterien ausrichten. Anhang16112020_MR_ DJSI_GER

Jacksonville, FL, Nov. 16, 2020 (GLOBE NEWSWIRE) — Global Warming Solution Inc., (OTC MARKETS: GWSO), is pleased to announce that effective today, three new members were added to it’s Advisory Committee. Prof. Robert F. Waters, Ph.D., Del Bentz M.S. and Bret W. Rawson brings decades of valuable leadership to Global Warming Solutions, Inc. About Prof. Robert F. WatersProf. Robert F. Waters, Ph.D. is a senior research professor at Arizona State University Biodesign Institute. He is co-developer of many successful anti-cancer and anti-viral treatments. His research includes focus in genomics, anti-virals, diabetes, cancer, artificial intelligence, and mathematics. He also continues to be published in major journals, and attends speaking engagements regularly.Prof. Robert F. Waters is a current member of the Mathematical Association of...

TORONTO, Nov. 15, 2020 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA), (“Captor” or the “Company”), announced today the Company’s common shares will no longer be traded through the facilities of the OTC in the United States. The U.S. Securities and Exchange Commission has revoked the registration of the Company’s securities under Section 12(j) of the Securities Exchange Act of 1934 for not filing continuous disclosure documents.  Captor remains a reporting issuer in good standing in each of British Columbia, Alberta and Ontario, and its common shares remain listed for trading on the Canadian Securities Exchange under the symbol CPTR.About Captor Capital Corp.Captor Capital Corp. is a Canadian vertically integrated cannabis company listed on the Canadian Securities Exchange,...

DME fiscal Q1 revenue grew 10.4% year-over-year and 5.0% sequentially highlighting the business’ ability to grow despite the negative impact from COVID-19 on new equipment rental set-upsDME fiscal Q1 net loss of $0.5 million improved from a net loss of $0.8 million year-over-year while adjusted EBITDA of $2.8 million decreased from $3.0 million primarily reflecting the incremental costs of operating during the pandemicInvestment Management is poised for growth in AUM, revenue, and earnings following the successful completion of the $31.7 million GECC rights offeringWALTHAM, Mass., Nov. 15, 2020 (GLOBE NEWSWIRE) — Great Elm Capital Group, Inc. (NASDAQ: GEC, “Great Elm”) announced its financial results for the quarter ended September 30, 2020. Great Elm will host a conference call and webcast on Monday, November 16, 2020 at 8:00 a.m....

GUANGZHOU, China, Nov. 15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into a development and commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad”) which will bring myChoice® tumor testing for homologous recombination deficiency, or HRD, to China.The Myriad myChoice CDx test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. In May 2020, the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with HRD-positive status, who are eligible or may become...

EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in CirculationMavacamten Treatment Resulted in Favorable Effect on Cardiac Structure — Significantly Reduced Hypertrophy in Patients with Hypertrophic CardiomyopathyBRISBANE, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) announced results from its cardiac magnetic resonance imaging (CMR) substudy of mavacamten for the potential treatment of hypertrophic cardiomyopathy (HCM) showing that 30-week treatment with mavacamten has a favorable effect on cardiac structure, while maintaining contractile function within the normal range. These data were shared today in an oral presentation titled, “Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR...

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted        In the 60 mg every 4 weeks multi-dose cohort, HBsAg concentrations continued to decline steadily beyond week 12 with no plateau in response observed to date          Both HBV RNA and HBcrAg concentrations declined after single- and multi-dose administration of AB-729          AB-729 was generally safe and well toleratedConference Call and Webcast Scheduled for Monday, November 16, 2020 at 8:00 am ETWARMINSTER, Pa., Nov. 15, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection...

PROLOGUECHIFFRE D’AFFAIRES DE 16,9 M€ AU T3 2020 EN BAISSE DE -6,7% (-5,7% A CHANGE CONSTANT)CROISSANCE DE TOUTES LES ACTIVITÉS HORS FORMATIONCROISSANCE DES ACTIVITÉS CLOUD DE +12,6% (+20,0% À CHANGE CONSTANT)LINKBYNET INTÈGRE LA TECHNOLOGIE INVENTORY DE USE IT CLOUD À SA CMDBDÉBUT DE REBOND DE L’ACTIVITÉ FORMATION TOUJOURS MARQUÉE PAR LA CRISE SANITAIRE*(données non auditées)  ** (D à taux de change constant)CROISSANCE DE TOUTES LES ACTIVITÉS HORS FORMATIONLe groupe Prologue a enregistré au 3ème trimestre 2020 un chiffre d’affaires de 16,86 M€ en baisse de -6,7% (-5,7% à change constant). Hors activité de formation, la croissance du groupe atteint sur cette période +13,7% (à change constant).  CROISSANCE DE +12,6% (+20,0% A CHANGE CONTANT) DES ACTIVITÉS CLOUD ET SERVICES MANAGÉSL’activité Cloud et Services Managés a enregistré sur le...

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, November 16th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed...